Phase 1 study of dalotuzumab monotherapy and ridaforolimus-dalotuzumab combination therapy in paediatric patients with advanced solid tumours
详细信息 查看全文
- 作者：Didier Frappaza ; Sara M. Federicob ; Andrew D.J. Pearsonc ; Lia Gored ; e ; Margaret E. Macyd ; e ; Steven G. DuBoisf ; Isabelle Aertsg ; Robert Iannoneh ; Ryan Geschwindth ; Arne Van Schankei ; Rui Wangj ; Birgit Geoergerk ; birgit.geoerger@gustaveroussy.fr" class="auth_mail" title="E-mail the corresponding author
- 关键词：Dalotuzumab ; Ridaforolimus ; mTOR ; IGF1-R ; Paediatrics ; Phase 1 ; Pharmacokinetics
- 刊名：European Journal of Cancer
- 出版年：2016
- 出版时间：July 2016
- 年：2016
- 卷：62
- 期：Complete
- 页码：9-17
- 全文大小：437 K
文摘
- •
No dose-limiting toxicities with single-agent dalotuzumab.
- •
Pharmacokinetic data were similar to previous data reported in adults.
- •
No pharmacokinetic interactions for combination of dalotuzumab and ridaforolimus.
- •
Dalotuzumab and ridaforolimus warrant further evaluation in paediatric patients.
- •
An objective response to dalotuzumab was observed in one patient with Ewing sarcoma.